Loading stock data…
BioHarvest Sciences Inc (BHST)
$2.79+0.02 (+0.72%)
Market ClosedLast close Jun 29
BioHarvest Sciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioHarvest Sciences Inc. Common Stock in the Consumer Defensive sector is trading at $2.79 with a market capitalization of $80M. Wall Street consensus targets $12.75 (4 analysts), implying a +357.0% move over the next 12 months. The stock is currently near its 52-week low of $2.75, remaining 52.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +357.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.51M↓ | $9.07M | $9.07M↑ | $8.52M↑ | $7.86M |
| Gross Profit | $5.04M↓ | $5.22M↓ | $5.57M↑ | $5.09M↑ | $4.59M |
| Operating Income | -$1.83M↓ | -$1.12M↓ | -$920,000↑ | -$1.81M↓ | -$1.72M |
| Net Income | -$2.64M↓ | -$2.20M↑ | -$2.51M↑ | -$4.08M↓ | -$2.34M |
Peer Comparison
Fundamentals
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with highe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.68%
Volume
Today's trading volume
3,413
Recent News
BioHarvest Sciences and Tate & Lyle expand sweetener development program
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an...
BioHarvest (BHST) Q1 2026 Earnings Transcript
Zaki Rakib: Thank you, Dory, and thank you all for joining us this morning. BioHarvest Sciences is an industrial plant cell culture biotech company and a leader in Botanical Synthesis, which is a patented non-GMO platform technology that industrializes what nature otherwise does slowly and produces high-value plant-derived compounds and botanical compositions without growing the plant itself. Using proprietary plant cell biology, elicitation technologies, AI-driven development and industrial scale bioreactors, BioHarvest creates highly consistent, bioavailable and patent-protected precision botanics or compounds possessing enhanced potency and purity compared to the original plant, along with the characteristics for commercial scalability.
BioHarvest Sciences Inc. Common Stock Q1 2026 Earnings Call Summary
Moby summary of BioHarvest Sciences Inc. Common Stock's Q1 2026 earnings call
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
BioHarvest Sciences Inc (BHST) reports an 8% revenue increase and strategic advancements, despite facing higher net losses and operating expenses.
BioHarvest Sciences Q1 Earnings Call Highlights
BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat